AMGN
Amgen Inc.
AMGN
(3.2)336,53 USD
12.23% ROA
103.27% ROE
21.51x PER
162.809.175.270,00 USD
789.81% DER
2.8% Yield
23.83% NPM
Amgen Inc. Stock Analysis
Amgen Inc. Fundamental Analysis
Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.
| # | Analysis | Rating |
|---|---|---|
| 1 |
ROE
The stock's ROE exceeds expectations (129.08%), revealing strong profitability and efficient use of shareholders' equity, making it an attractive investment opportunity. |
|
| 2 |
ROA
This stock has a great ability to make a lot of money from the things it owns, which makes it a really good investment for smart investors. |
|
| 3 |
Revenue Growth
Over the past five years, this company's revenue has consistently increased, demonstrating a robust financial performance that makes it an appealing opportunity. |
|
| 4 |
Dividend Growth
The company has demonstrated exceptional dividend growth over the past five years, consistently increasing payouts to shareholders year after year. |
|
| 5 |
Dividend
Investors can take comfort in the company's unwavering commitment to dividends, as it has consistently distributed payouts over the past five years, ensuring a reliable income stream. |
|
| 6 |
Net Profit Growth
Throughout the last three years, this company has experienced consistent net profit growth, reflecting a robust financial performance and making it an attractive investment prospect. |
|
| 7 |
Assets Growth
Over the past three years, this company's revenue has consistently grown, demonstrating a positive financial trend that makes it an appealing choice. |
|
| 8 |
Buffet Intrinsic Value
Warren Buffett's formula suggests that the company's stock is undervalued (948), making it an appealing investment prospect with its intrinsic value surpassing the current market price. |
|
| 9 |
PBV
The stock's high Price-to-Book Value (P/BV) ratio (18.55x) suggests it's overvalued, potentially making it an expensive investment. |
|
| 10 |
DER
The stock is burdened with a heavy load of debt (790%), making it financially unstable and potentially risky for investors. |
|
| 11 |
Graham Number
The Graham number of this company suggests that its stock price may be overvalued, indicating a less favorable investment opportunity. |
Amgen Inc. Technical Analysis
Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.
| # | Analysis | Recommendation |
|---|---|---|
| 1 | Awesome Oscillator | Sell |
| 2 | MACD | Sell |
| 3 | RSI | Hold |
| 4 | Stoch RSI | Sell |
Amgen Inc. Price Chart
Financial Statements
Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.
Income Statements
An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.
Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.
| Year | Revenue | Growth |
|---|---|---|
| 1986 | 21.100.000 | |
| 1987 | 29.800.000 | 29.19% |
| 1988 | 44.300.000 | 32.73% |
| 1989 | 70.200.000 | 36.89% |
| 1990 | 190.400.000 | 63.13% |
| 1991 | 679.800.000 | 71.99% |
| 1992 | 1.080.300.000 | 37.07% |
| 1993 | 1.354.900.000 | 20.27% |
| 1994 | 1.620.000.000 | 16.36% |
| 1995 | 1.903.800.000 | 14.91% |
| 1996 | 2.198.100.000 | 13.39% |
| 1997 | 2.345.700.000 | 6.29% |
| 1998 | 2.642.300.000 | 11.23% |
| 1999 | 3.204.200.000 | 17.54% |
| 2000 | 3.448.400.000 | 7.08% |
| 2001 | 4.015.700.000 | 14.13% |
| 2002 | 5.523.000.000 | 27.29% |
| 2003 | 8.356.000.000 | 33.9% |
| 2004 | 10.550.000.000 | 20.8% |
| 2005 | 12.430.000.000 | 15.12% |
| 2006 | 14.268.000.000 | 12.88% |
| 2007 | 14.771.000.000 | 3.41% |
| 2008 | 15.003.000.000 | 1.55% |
| 2009 | 14.642.000.000 | -2.47% |
| 2010 | 15.053.000.000 | 2.73% |
| 2011 | 15.582.000.000 | 3.39% |
| 2012 | 17.265.000.000 | 9.75% |
| 2013 | 18.676.000.000 | 7.56% |
| 2014 | 20.063.000.000 | 6.91% |
| 2015 | 21.662.000.000 | 7.38% |
| 2016 | 22.991.000.000 | 5.78% |
| 2017 | 22.849.000.000 | -0.62% |
| 2018 | 23.747.000.000 | 3.78% |
| 2019 | 23.362.000.000 | -1.65% |
| 2020 | 25.424.000.000 | 8.11% |
| 2021 | 25.979.000.000 | 2.14% |
| 2022 | 26.323.000.000 | 1.31% |
| 2023 | 27.612.000.000 | 4.67% |
Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.
| Year | Research and Development Expenses | Growth |
|---|---|---|
| 1986 | 0 | |
| 1987 | 0 | 0% |
| 1988 | 0 | 0% |
| 1989 | 0 | 0% |
| 1990 | 0 | 0% |
| 1991 | 0 | 0% |
| 1992 | 0 | 0% |
| 1993 | 0 | 0% |
| 1994 | 323.600.000 | 100% |
| 1995 | 451.700.000 | 28.36% |
| 1996 | 528.300.000 | 14.5% |
| 1997 | 630.800.000 | 16.25% |
| 1998 | 663.300.000 | 4.9% |
| 1999 | 822.800.000 | 19.39% |
| 2000 | 845.000.000 | 2.63% |
| 2001 | 865.000.000 | 2.31% |
| 2002 | 1.116.600.000 | 22.53% |
| 2003 | 1.655.400.000 | 32.55% |
| 2004 | 2.028.000.000 | 18.37% |
| 2005 | 2.314.000.000 | 12.36% |
| 2006 | 3.366.000.000 | 31.25% |
| 2007 | 3.266.000.000 | -3.06% |
| 2008 | 3.030.000.000 | -7.79% |
| 2009 | 2.864.000.000 | -5.8% |
| 2010 | 2.894.000.000 | 1.04% |
| 2011 | 3.167.000.000 | 8.62% |
| 2012 | 3.380.000.000 | 6.3% |
| 2013 | 4.083.000.000 | 17.22% |
| 2014 | 4.297.000.000 | 4.98% |
| 2015 | 4.070.000.000 | -5.58% |
| 2016 | 3.840.000.000 | -5.99% |
| 2017 | 3.562.000.000 | -7.8% |
| 2018 | 3.737.000.000 | 4.68% |
| 2019 | 4.116.000.000 | 9.21% |
| 2020 | 4.207.000.000 | 2.16% |
| 2021 | 4.819.000.000 | 12.7% |
| 2022 | 4.434.000.000 | -8.68% |
| 2023 | 4.316.000.000 | -2.73% |
General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.
| Year | General and Administrative Expenses | Growth |
|---|---|---|
| 1986 | 22.000.000 | |
| 1987 | 6.800.000 | -223.53% |
| 1988 | 10.300.000 | 33.98% |
| 1989 | 23.000.000 | 55.22% |
| 1990 | 134.600.000 | 82.91% |
| 1991 | 0 | 0% |
| 1992 | 397.400.000 | 100% |
| 1993 | 583.700.000 | 31.92% |
| 1994 | 359.800.000 | -62.23% |
| 1995 | 418.400.000 | 14.01% |
| 1996 | 470.600.000 | 11.09% |
| 1997 | 483.800.000 | 2.73% |
| 1998 | 515.400.000 | 6.13% |
| 1999 | 654.300.000 | 21.23% |
| 2000 | 826.900.000 | 20.87% |
| 2001 | 970.700.000 | 14.81% |
| 2002 | 1.462.100.000 | 33.61% |
| 2003 | 1.952.600.000 | 25.12% |
| 2004 | 2.556.000.000 | 23.61% |
| 2005 | 2.790.000.000 | 8.39% |
| 2006 | 3.366.000.000 | 17.11% |
| 2007 | 3.361.000.000 | -0.15% |
| 2008 | 3.789.000.000 | 11.3% |
| 2009 | 3.820.000.000 | 0.81% |
| 2010 | 3.983.000.000 | 4.09% |
| 2011 | 4.486.000.000 | 11.21% |
| 2012 | 4.801.000.000 | 6.56% |
| 2013 | 5.184.000.000 | 7.39% |
| 2014 | 4.699.000.000 | -10.32% |
| 2015 | 4.846.000.000 | 3.03% |
| 2016 | 5.062.000.000 | 4.27% |
| 2017 | 4.870.000.000 | -3.94% |
| 2018 | 5.332.000.000 | 8.66% |
| 2019 | 0 | 0% |
| 2020 | 0 | 0% |
| 2021 | 0 | 0% |
| 2022 | 0 | 0% |
| 2023 | 0 | 0% |
EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.
| Year | EBITDA | Growth |
|---|---|---|
| 1986 | 3.100.000 | |
| 1987 | -1.800.000 | 272.22% |
| 1988 | -9.500.000 | 81.05% |
| 1989 | 5.300.000 | 279.25% |
| 1990 | 37.500.000 | 85.87% |
| 1991 | 109.000.000 | 65.6% |
| 1992 | 466.600.000 | 76.64% |
| 1993 | 554.500.000 | 15.85% |
| 1994 | 871.200.000 | 36.35% |
| 1995 | 796.100.000 | -9.43% |
| 1996 | 963.800.000 | 17.4% |
| 1997 | 1.112.600.000 | 13.37% |
| 1998 | 1.146.200.000 | 2.93% |
| 1999 | 1.333.700.000 | 14.06% |
| 2000 | 1.404.000.000 | 5.01% |
| 2001 | 1.750.200.000 | 19.78% |
| 2002 | 12.597.100.000 | 86.11% |
| 2003 | 3.758.000.000 | -235.21% |
| 2004 | 5.190.000.000 | 27.59% |
| 2005 | 5.738.000.000 | 9.55% |
| 2006 | 7.265.000.000 | 21.02% |
| 2007 | 7.299.000.000 | 0.47% |
| 2008 | 6.667.000.000 | -9.48% |
| 2009 | 6.076.000.000 | -9.73% |
| 2010 | 6.215.000.000 | 2.24% |
| 2011 | 5.054.000.000 | -22.97% |
| 2012 | 6.356.000.000 | 20.48% |
| 2013 | 6.287.000.000 | -1.1% |
| 2014 | 6.656.000.000 | 5.54% |
| 2015 | 9.073.000.000 | 26.64% |
| 2016 | 10.423.000.000 | 12.95% |
| 2017 | 10.901.000.000 | 4.38% |
| 2018 | 10.937.000.000 | 0.33% |
| 2019 | 10.427.000.000 | -4.89% |
| 2020 | 9.395.000.000 | -10.98% |
| 2021 | 9.403.000.000 | 0.09% |
| 2022 | 8.752.000.000 | -7.44% |
| 2023 | 10.824.000.000 | 19.14% |
Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.
| Year | Gross Profit | Growth |
|---|---|---|
| 1986 | 23.600.000 | |
| 1987 | 8.000.000 | -195% |
| 1988 | 8.800.000 | 9.09% |
| 1989 | 26.200.000 | 66.41% |
| 1990 | 175.700.000 | 85.09% |
| 1991 | 588.600.000 | 70.15% |
| 1992 | 929.100.000 | 36.65% |
| 1993 | 1.185.600.000 | 21.63% |
| 1994 | 1.456.400.000 | 18.59% |
| 1995 | 1.715.100.000 | 15.08% |
| 1996 | 2.015.200.000 | 14.89% |
| 1997 | 2.162.000.000 | 6.79% |
| 1998 | 2.440.900.000 | 11.43% |
| 1999 | 2.978.900.000 | 18.06% |
| 2000 | 3.251.800.000 | 8.39% |
| 2001 | 3.572.700.000 | 8.98% |
| 2002 | 4.787.300.000 | 25.37% |
| 2003 | 7.015.300.000 | 31.76% |
| 2004 | 8.819.000.000 | 20.45% |
| 2005 | 10.348.000.000 | 14.78% |
| 2006 | 12.173.000.000 | 14.99% |
| 2007 | 12.223.000.000 | 0.41% |
| 2008 | 12.707.000.000 | 3.81% |
| 2009 | 12.551.000.000 | -1.24% |
| 2010 | 12.833.000.000 | 2.2% |
| 2011 | 13.155.000.000 | 2.45% |
| 2012 | 14.347.000.000 | 8.31% |
| 2013 | 15.330.000.000 | 6.41% |
| 2014 | 15.641.000.000 | 1.99% |
| 2015 | 17.435.000.000 | 10.29% |
| 2016 | 18.829.000.000 | 7.4% |
| 2017 | 18.780.000.000 | -0.26% |
| 2018 | 19.646.000.000 | 4.41% |
| 2019 | 19.006.000.000 | -3.37% |
| 2020 | 19.265.000.000 | 1.34% |
| 2021 | 19.525.000.000 | 1.33% |
| 2022 | 19.917.000.000 | 1.97% |
| 2023 | 20.388.000.000 | 2.31% |
Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.
| Year | Net Profit | Growth |
|---|---|---|
| 1986 | 500.000 | |
| 1987 | 800.000 | 37.5% |
| 1988 | 1.700.000 | 52.94% |
| 1989 | -8.200.000 | 120.73% |
| 1990 | 19.100.000 | 142.93% |
| 1991 | 97.900.000 | 80.49% |
| 1992 | 357.600.000 | 72.62% |
| 1993 | 383.300.000 | 6.7% |
| 1994 | 319.700.000 | -19.89% |
| 1995 | 537.700.000 | 40.54% |
| 1996 | 679.800.000 | 20.9% |
| 1997 | 644.300.000 | -5.51% |
| 1998 | 863.200.000 | 25.36% |
| 1999 | 1.096.400.000 | 21.27% |
| 2000 | 1.138.500.000 | 3.7% |
| 2001 | 1.119.700.000 | -1.68% |
| 2002 | -1.391.900.000 | 180.44% |
| 2003 | 2.259.500.000 | 161.6% |
| 2004 | 2.363.000.000 | 4.38% |
| 2005 | 3.674.000.000 | 35.68% |
| 2006 | 2.950.000.000 | -24.54% |
| 2007 | 3.166.000.000 | 6.82% |
| 2008 | 4.196.000.000 | 24.55% |
| 2009 | 4.605.000.000 | 8.88% |
| 2010 | 4.627.000.000 | 0.48% |
| 2011 | 3.683.000.000 | -25.63% |
| 2012 | 4.345.000.000 | 15.24% |
| 2013 | 5.081.000.000 | 14.49% |
| 2014 | 5.158.000.000 | 1.49% |
| 2015 | 6.939.000.000 | 25.67% |
| 2016 | 7.722.000.000 | 10.14% |
| 2017 | 1.979.000.000 | -290.2% |
| 2018 | 8.394.000.000 | 76.42% |
| 2019 | 7.842.000.000 | -7.04% |
| 2020 | 7.264.000.000 | -7.96% |
| 2021 | 5.893.000.000 | -23.26% |
| 2022 | 6.552.000.000 | 10.06% |
| 2023 | 6.920.000.000 | 5.32% |
EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.
| Year | Earning per Share (EPS) | Growth |
|---|---|---|
| 1986 | 0 | |
| 1987 | 0 | 0% |
| 1988 | 0 | 0% |
| 1989 | 0 | 0% |
| 1990 | 0 | 0% |
| 1991 | 0 | 0% |
| 1992 | 0 | 0% |
| 1993 | 0 | 0% |
| 1994 | 0 | 0% |
| 1995 | 0 | 0% |
| 1996 | 1 | 0% |
| 1997 | 1 | 0% |
| 1998 | 1 | 0% |
| 1999 | 1 | 100% |
| 2000 | 1 | 0% |
| 2001 | 1 | 0% |
| 2002 | -1 | 200% |
| 2003 | 2 | 200% |
| 2004 | 2 | 0% |
| 2005 | 3 | 50% |
| 2006 | 3 | 0% |
| 2007 | 3 | 0% |
| 2008 | 4 | 33.33% |
| 2009 | 5 | 25% |
| 2010 | 5 | 0% |
| 2011 | 4 | 0% |
| 2012 | 6 | 20% |
| 2013 | 7 | 16.67% |
| 2014 | 7 | 0% |
| 2015 | 9 | 33.33% |
| 2016 | 10 | 10% |
| 2017 | 3 | -400% |
| 2018 | 13 | 83.33% |
| 2019 | 13 | 0% |
| 2020 | 12 | 0% |
| 2021 | 10 | -20% |
| 2022 | 12 | 16.67% |
| 2023 | 13 | 0% |
Cashflow Statements
Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.
Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.
| Year | Free Cashflow | Growth |
|---|---|---|
| 1989 | -49.100.000 | |
| 1990 | -25.400.000 | -93.31% |
| 1991 | 102.400.000 | 124.8% |
| 1992 | 73.000.000 | -40.27% |
| 1993 | 223.100.000 | 67.28% |
| 1994 | 401.100.000 | 44.38% |
| 1995 | 610.500.000 | 34.3% |
| 1996 | 555.700.000 | -9.86% |
| 1997 | 515.100.000 | -7.88% |
| 1998 | 633.700.000 | 18.72% |
| 1999 | 771.100.000 | 17.82% |
| 2000 | 1.196.900.000 | 35.58% |
| 2001 | 1.038.400.000 | -15.26% |
| 2002 | 1.590.300.000 | 34.7% |
| 2003 | 2.209.800.000 | 28.03% |
| 2004 | 2.361.000.000 | 6.4% |
| 2005 | 4.044.000.000 | 41.62% |
| 2006 | 4.171.000.000 | 3.04% |
| 2007 | 4.134.000.000 | -0.9% |
| 2008 | 5.316.000.000 | 22.23% |
| 2009 | 5.806.000.000 | 8.44% |
| 2010 | 5.207.000.000 | -11.5% |
| 2011 | 4.552.000.000 | -14.39% |
| 2012 | 5.193.000.000 | 12.34% |
| 2013 | 5.598.000.000 | 7.23% |
| 2014 | 7.552.000.000 | 25.87% |
| 2015 | 8.428.000.000 | 10.39% |
| 2016 | 9.517.000.000 | 11.44% |
| 2017 | 10.513.000.000 | 9.47% |
| 2018 | 10.558.000.000 | 0.43% |
| 2019 | 8.532.000.000 | -23.75% |
| 2020 | 9.889.000.000 | 13.72% |
| 2021 | 8.381.000.000 | -17.99% |
| 2022 | 8.785.000.000 | 4.6% |
| 2023 | 2.760.000.000 | -218.3% |
Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.
| Year | Operating Cashflow | Growth |
|---|---|---|
| 1989 | -5.900.000 | |
| 1990 | 18.700.000 | 131.55% |
| 1991 | 219.700.000 | 91.49% |
| 1992 | 292.800.000 | 24.97% |
| 1993 | 433.000.000 | 32.38% |
| 1994 | 531.900.000 | 18.59% |
| 1995 | 773.200.000 | 31.21% |
| 1996 | 822.600.000 | 6.01% |
| 1997 | 902.900.000 | 8.89% |
| 1998 | 1.041.500.000 | 13.31% |
| 1999 | 1.075.300.000 | 3.14% |
| 2000 | 1.634.600.000 | 34.22% |
| 2001 | 1.480.200.000 | -10.43% |
| 2002 | 2.248.800.000 | 34.18% |
| 2003 | 3.566.600.000 | 36.95% |
| 2004 | 3.697.000.000 | 3.53% |
| 2005 | 4.911.000.000 | 24.72% |
| 2006 | 5.389.000.000 | 8.87% |
| 2007 | 5.401.000.000 | 0.22% |
| 2008 | 5.988.000.000 | 9.8% |
| 2009 | 6.336.000.000 | 5.49% |
| 2010 | 5.787.000.000 | -9.49% |
| 2011 | 5.119.000.000 | -13.05% |
| 2012 | 5.882.000.000 | 12.97% |
| 2013 | 6.291.000.000 | 6.5% |
| 2014 | 8.555.000.000 | 26.46% |
| 2015 | 9.077.000.000 | 5.75% |
| 2016 | 10.354.000.000 | 12.33% |
| 2017 | 11.177.000.000 | 7.36% |
| 2018 | 11.296.000.000 | 1.05% |
| 2019 | 9.150.000.000 | -23.45% |
| 2020 | 10.497.000.000 | 12.83% |
| 2021 | 9.261.000.000 | -13.35% |
| 2022 | 9.721.000.000 | 4.73% |
| 2023 | 2.760.000.000 | -252.21% |
Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.
| Year | Capital Expenditure | Growth |
|---|---|---|
| 1989 | 43.200.000 | |
| 1990 | 44.100.000 | 2.04% |
| 1991 | 117.300.000 | 62.4% |
| 1992 | 219.800.000 | 46.63% |
| 1993 | 209.900.000 | -4.72% |
| 1994 | 130.800.000 | -60.47% |
| 1995 | 162.700.000 | 19.61% |
| 1996 | 266.900.000 | 39.04% |
| 1997 | 387.800.000 | 31.18% |
| 1998 | 407.800.000 | 4.9% |
| 1999 | 304.200.000 | -34.06% |
| 2000 | 437.700.000 | 30.5% |
| 2001 | 441.800.000 | 0.93% |
| 2002 | 658.500.000 | 32.91% |
| 2003 | 1.356.800.000 | 51.47% |
| 2004 | 1.336.000.000 | -1.56% |
| 2005 | 867.000.000 | -54.09% |
| 2006 | 1.218.000.000 | 28.82% |
| 2007 | 1.267.000.000 | 3.87% |
| 2008 | 672.000.000 | -88.54% |
| 2009 | 530.000.000 | -26.79% |
| 2010 | 580.000.000 | 8.62% |
| 2011 | 567.000.000 | -2.29% |
| 2012 | 689.000.000 | 17.71% |
| 2013 | 693.000.000 | 0.58% |
| 2014 | 1.003.000.000 | 30.91% |
| 2015 | 649.000.000 | -54.55% |
| 2016 | 837.000.000 | 22.46% |
| 2017 | 664.000.000 | -26.05% |
| 2018 | 738.000.000 | 10.03% |
| 2019 | 618.000.000 | -19.42% |
| 2020 | 608.000.000 | -1.64% |
| 2021 | 880.000.000 | 30.91% |
| 2022 | 936.000.000 | 5.98% |
| 2023 | 0 | 0% |
Balance Sheet
Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.
Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.
| Year | Equity | Growth |
|---|---|---|
| 1986 | 80.600.000 | |
| 1987 | 84.000.000 | 4.05% |
| 1988 | 163.500.000 | 48.62% |
| 1989 | 161.900.000 | -0.99% |
| 1990 | 188.100.000 | 13.93% |
| 1991 | 531.100.000 | 64.58% |
| 1992 | 933.700.000 | 43.12% |
| 1993 | 1.172.000.000 | 20.33% |
| 1994 | 1.274.300.000 | 8.03% |
| 1995 | 1.671.800.000 | 23.78% |
| 1996 | 1.906.300.000 | 12.3% |
| 1997 | 2.139.300.000 | 10.89% |
| 1998 | 2.562.200.000 | 16.51% |
| 1999 | 3.023.500.000 | 15.26% |
| 2000 | 4.314.500.000 | 29.92% |
| 2001 | 5.217.200.000 | 17.3% |
| 2002 | 18.286.000.000 | 71.47% |
| 2003 | 19.389.100.000 | 5.69% |
| 2004 | 19.705.000.000 | 1.6% |
| 2005 | 20.451.000.000 | 3.65% |
| 2006 | 18.964.000.000 | -7.84% |
| 2007 | 17.869.000.000 | -6.13% |
| 2008 | 20.386.000.000 | 12.35% |
| 2009 | 22.667.000.000 | 10.06% |
| 2010 | 23.944.000.000 | 5.33% |
| 2011 | 19.029.000.000 | -25.83% |
| 2012 | 19.060.000.000 | 0.16% |
| 2013 | 22.096.000.000 | 13.74% |
| 2014 | 25.778.000.000 | 14.28% |
| 2015 | 28.083.000.000 | 8.21% |
| 2016 | 29.875.000.000 | 6% |
| 2017 | 25.241.000.000 | -18.36% |
| 2018 | 12.500.000.000 | -101.93% |
| 2019 | 9.673.000.000 | -29.23% |
| 2020 | 9.409.000.000 | -2.81% |
| 2021 | 6.700.000.000 | -40.43% |
| 2022 | 3.661.000.000 | -83.01% |
| 2023 | 7.656.000.000 | 52.18% |
Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.
| Year | Assets | Growth |
|---|---|---|
| 1986 | 93.700.000 | |
| 1987 | 96.800.000 | 3.2% |
| 1988 | 192.800.000 | 49.79% |
| 1989 | 207.100.000 | 6.9% |
| 1990 | 308.100.000 | 32.78% |
| 1991 | 865.500.000 | 64.4% |
| 1992 | 1.374.300.000 | 37.02% |
| 1993 | 1.765.500.000 | 22.16% |
| 1994 | 1.994.100.000 | 11.46% |
| 1995 | 2.432.800.000 | 18.03% |
| 1996 | 2.765.600.000 | 12.03% |
| 1997 | 3.110.200.000 | 11.08% |
| 1998 | 3.672.200.000 | 15.3% |
| 1999 | 4.077.600.000 | 9.94% |
| 2000 | 5.399.600.000 | 24.48% |
| 2001 | 6.443.100.000 | 16.2% |
| 2002 | 24.456.300.000 | 73.65% |
| 2003 | 26.176.500.000 | 6.57% |
| 2004 | 29.221.000.000 | 10.42% |
| 2005 | 29.297.000.000 | 0.26% |
| 2006 | 33.788.000.000 | 13.29% |
| 2007 | 34.639.000.000 | 2.46% |
| 2008 | 36.443.000.000 | 4.95% |
| 2009 | 39.629.000.000 | 8.04% |
| 2010 | 43.486.000.000 | 8.87% |
| 2011 | 48.871.000.000 | 11.02% |
| 2012 | 54.298.000.000 | 9.99% |
| 2013 | 66.125.000.000 | 17.89% |
| 2014 | 69.009.000.000 | 4.18% |
| 2015 | 71.576.000.000 | 3.59% |
| 2016 | 77.626.000.000 | 7.79% |
| 2017 | 79.954.000.000 | 2.91% |
| 2018 | 66.416.000.000 | -20.38% |
| 2019 | 59.707.000.000 | -11.24% |
| 2020 | 62.948.000.000 | 5.15% |
| 2021 | 61.165.000.000 | -2.92% |
| 2022 | 65.121.000.000 | 6.07% |
| 2023 | 90.534.000.000 | 28.07% |
Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.
| Year | Liabilities | Growth |
|---|---|---|
| 1986 | 13.100.000 | |
| 1987 | 12.800.000 | -2.34% |
| 1988 | 29.300.000 | 56.31% |
| 1989 | 45.200.000 | 35.18% |
| 1990 | 120.000.000 | 62.33% |
| 1991 | 334.400.000 | 64.11% |
| 1992 | 440.600.000 | 24.1% |
| 1993 | 593.500.000 | 25.76% |
| 1994 | 719.800.000 | 17.55% |
| 1995 | 761.000.000 | 5.41% |
| 1996 | 859.300.000 | 11.44% |
| 1997 | 970.900.000 | 11.49% |
| 1998 | 1.110.000.000 | 12.53% |
| 1999 | 1.054.100.000 | -5.3% |
| 2000 | 1.085.100.000 | 2.86% |
| 2001 | 1.225.900.000 | 11.49% |
| 2002 | 6.170.300.000 | 80.13% |
| 2003 | 6.787.400.000 | 9.09% |
| 2004 | 9.516.000.000 | 28.67% |
| 2005 | 8.846.000.000 | -7.57% |
| 2006 | 14.824.000.000 | 40.33% |
| 2007 | 16.770.000.000 | 11.6% |
| 2008 | 16.057.000.000 | -4.44% |
| 2009 | 16.962.000.000 | 5.34% |
| 2010 | 19.542.000.000 | 13.2% |
| 2011 | 29.842.000.000 | 34.52% |
| 2012 | 35.238.000.000 | 15.31% |
| 2013 | 44.029.000.000 | 19.97% |
| 2014 | 43.231.000.000 | -1.85% |
| 2015 | 43.493.000.000 | 0.6% |
| 2016 | 47.751.000.000 | 8.92% |
| 2017 | 54.713.000.000 | 12.72% |
| 2018 | 53.916.000.000 | -1.48% |
| 2019 | 50.034.000.000 | -7.76% |
| 2020 | 53.539.000.000 | 6.55% |
| 2021 | 54.465.000.000 | 1.7% |
| 2022 | 61.460.000.000 | 11.38% |
| 2023 | 82.878.000.000 | 25.84% |
Amgen Inc. Financial Ratio (TTM)
Valuation Metrics
- Revenue per Share
- 50.16
- Net Income per Share
- 14.14
- Price to Earning Ratio
- 21.51x
- Price To Sales Ratio
- 6.07x
- POCF Ratio
- 15.38
- PFCF Ratio
- 16.91
- Price to Book Ratio
- 21.26
- EV to Sales
- 7.03
- EV Over EBITDA
- 16.8
- EV to Operating CashFlow
- 17.82
- EV to FreeCashFlow
- 19.58
- Earnings Yield
- 0.05
- FreeCashFlow Yield
- 0.06
- Market Cap
- 162,81 Bil.
- Enterprise Value
- 188,54 Bil.
- Graham Number
- 67.48
- Graham NetNet
- -76.66
Income Statement Metrics
- Net Income per Share
- 14.14
- Income Quality
- 1.81
- ROE
- 1.29
- Return On Assets
- 0.07
- Return On Capital Employed
- 0.12
- Net Income per EBT
- 0.86
- EBT Per Ebit
- 0.87
- Ebit per Revenue
- 0.32
- Effective Tax Rate
- 0.14
Margins
- Sales, General, & Administrative to Revenue
- 0
- Research & Developement to Revenue
- 0.17
- Stock Based Compensation to Revenue
- 0.03
- Gross Profit Margin
- 0.7
- Operating Profit Margin
- 0.32
- Pretax Profit Margin
- 0.28
- Net Profit Margin
- 0.24
Dividends
- Dividend Yield
- 0.03
- Dividend Yield %
- 2.8
- Payout Ratio
- 0.59
- Dividend Per Share
- 8.52
Operating Metrics
- Operating Cashflow per Share
- 19.78
- Free CashFlow per Share
- 17.99
- Capex to Operating CashFlow
- -0.09
- Capex to Revenue
- -0.04
- Capex to Depreciation
- -0.35
- Return on Invested Capital
- 0.11
- Return on Tangible Assets
- 0.12
- Days Sales Outstanding
- 83.59
- Days Payables Outstanding
- 69.95
- Days of Inventory on Hand
- 258.89
- Receivables Turnover
- 4.37
- Payables Turnover
- 5.22
- Inventory Turnover
- 1.41
- Capex per Share
- -1.79
Balance Sheet
- Cash per Share
- 64,94
- Book Value per Share
- 14,31
- Tangible Book Value per Share
- -39.26
- Shareholders Equity per Share
- 14.31
- Interest Debt per Share
- 117.64
- Debt to Equity
- 7.9
- Debt to Assets
- 0.67
- Net Debt to EBITDA
- 2.29
- Current Ratio
- 2.86
- Tangible Asset Value
- -21,00 Bil.
- Net Current Asset Value
- -34,40 Bil.
- Invested Capital
- 7.9
- Working Capital
- 31,52 Bil.
- Intangibles to Total Assets
- 0.32
- Average Receivables
- 5,99 Bil.
- Average Payables
- 1,29 Bil.
- Average Inventory
- 5002000000
- Debt to Market Cap
- 0.37
Dividends
Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.
| Year | Dividends | Growth |
|---|---|---|
| 2011 | 1 | |
| 2012 | 1 | 100% |
| 2013 | 2 | 0% |
| 2014 | 2 | 50% |
| 2015 | 3 | 33.33% |
| 2016 | 4 | 25% |
| 2017 | 5 | 0% |
| 2018 | 5 | 20% |
| 2019 | 6 | 0% |
| 2020 | 6 | 16.67% |
| 2021 | 7 | 14.29% |
| 2022 | 8 | 0% |
| 2023 | 9 | 12.5% |
Amgen Inc. Profile
About Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
- CEO
- Mr. Robert A. Bradway
- Employee
- 26.700
- Address
-
One Amgen Center Drive
Thousand Oaks, 91320-1799
Amgen Inc. Executives & BODs
| # | Name | Age |
|---|---|---|
| 1 |
Mr. Jonathan P. Graham Executive Vice President, General Counsel & Secretary |
70 |
| 2 |
Justin G. Claeys Vice President of Investor Relations |
70 |
| 3 |
Dr. David M. Reese M.D. Executive Vice President & Chief Technology Officer |
70 |
| 4 |
Mr. Robert A. Bradway Chairman, Chief Executive Officer & President |
70 |
| 5 |
Mr. Matthew C. Busch Chief Accounting Officer & Vice President of Finance |
70 |
| 6 |
Dr. James E. Bradner M.D. Executive Vice President of Research and Development & Chief Scientific Officer |
70 |
| 7 |
Mr. Peter H. Griffith Executive Vice President & Chief Financial Officer |
70 |
| 8 |
Mr. Esteban Santos Executive Vice President of Operations |
70 |
| 9 |
Mr. Murdo Gordon Executive Vice President of Global Commercial Operations |
70 |
| 10 |
Mr. Mike Zahigian Senior Vice President & Chief Information Officer |
70 |
Amgen Inc. Competitors
